Recently, the Municipal Science and Technology Bureau issued the “Announcement of the List of the Second Batch of Eagle Enterprises, Gazelle Enterprises and Science and Technology Leading (Cultivating) Enterprises in Tianjin in 2024,” and ProteinT was successfully recognized as a “Gazelle Enterprise.”

As a national high-tech enterprise focused on the frontier multi-omics field of precision medicine, ProteinT is committed to continuously advancing medical technology innovation and its commercialization and clinical application. This approval marks the rapid growth of our technological innovation capability, product value and growth potential, along with outstanding comprehensive benefits, strong industry influence, high social credibility and strong demonstration and driving effects. In the future, ProteinT will continue to strengthen technology research and development, enhance its independent innovation capability, continuously increase its core competitiveness, and continue to deepen its work in proteomics and other multi-omics fields to provide clinicians and patients with higher-quality products and services.

Refers to small and medium-sized enterprises that, after crossing the valley of death following startup, have entered a high-growth phase supported by scientific and technological innovation or business model innovation. Such enterprises are highly innovative and grow faster and faster, much like gazelles that are good at leaping and running, hence the name gazelle enterprise.